GENETIC ANALYSIS Aktie

 

OSLO, NORWAY – March 12: Genetic Analysis AS (“GA” or “the Company”) today announces the launch of GA-map® Dysbiosis Test AInsight (“AInsight”), an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice. The GA-map® Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient's microbiome profile to a healthy reference population. While microbiome analysis...

OSLO, NORWAY – February 27, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the year-end report for 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysis, comments: “The fourth quarter reflects continued execution of our long-term growth strategy, with progress in both commercial expansion and product development. We are advancing collaborations with industry partners, further strengthening the position of GA-map® technology in microbiome-related clinical...

OSLO, NORWAY – February 26, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that the year-end report for 2025 will be published on Friday, 27 February 2026. The Company's financial calendar for 2025 was included in the interim report for the first quarter of 2025, in which it was stated that the year-end report for 2025 would be published on 27 February 2026. This date has also been published on the Company's website and on Spotlight Stock Market's company page. However an incorrect publication date (25 February 2026) was stated in the interim report for the third quarter of...

OSLO, NORWAY – February 19, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that its patent application US2017/0369941 has been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent, entitled “METHOD FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP'S”, strengthens the protection of GA's proprietary diagnostic technology. GA maintains an active patent strategy covering all major geographical markets and has previously announced approval in the EU and other countries for this patent. CEO Ronny Hermansen comments: ”High analytical accuracy...

OSLO, NORWAY – February 12, 2026: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that its important patent application CA2980637) has now been allowed for grant in Canada.  The important patent entitled “METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” covers the Company's unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. GA has an active patent strategy covering all major geographical markets and has previously announced approval in EU, China and other countries for this patent. The subject matter of this family of...

MIAMI, Jan. 15, 2026 /PRNewswire/ -- SelfDecode, a leader in AI-driven precision health and genetic analysis, supports the DNA Traits experience offered by MyHeritage, one of the world's largest consumer DNA and family history platforms. MyHeritage serves more than 8 million DNA customers......

OSLO, NORWAY – November 27, 2025: Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for Q3, and the first nine months of 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysis, comments: “The third quarter was marked by consistent progress across Genetic Analysis' commercial and development activities, underscoring continued execution on our long-term growth strategy. The third quarter was influenced by the slower summer holiday period, but sales...

OSLO, NORWAY – 17 November 2025: Microbiome DX company Genetic Analysis AS (“GA”) is pleased to announce the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development. The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in...

OSLO, NORWAY, September 26, 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at the Biomarkers & Precision Medicine congress in London, 30 September - 01 October 2025. The event offers a chance to gain the latest insights from across the biomarker and precision medicine landscape, while providing valuable networking and partnering opportunities. Genetic Analysis' Head of Commercial, Kari Furu, will attend the congress. GA will use the event to highlight GA's microbiome testing platform, GA-map®, demonstrating how it can be used in the development of new...

OSLO, NORWAY – 24 September 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces the launch of a novel Research Use Only (RUO) reagent kit, the GA-map® MHI GutHealth. The test provides an advanced tool for measuring antibiotic-induced microbiome imbalances and has been validated for recurrent Clostridioides difficile infection (rCDI). With this launch, GA-map® MHI GutHealth is made available for Luminex xMAP® users globally. As communicated on December 20, 2024, GA and Ferring Pharmaceuticals announced a collaboration to develop a new microbiome diagnostic test. Since then, GA...

OSLO, NORWAY – August 27 2025: Genetic Analysis AS ("GA" or the "Company") hereby publishes the half-year report for H1, and April - June 2025. The Half-year report is available as an attached file to this release and on the Company's website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysis, comments: “The first half of 2025 has reinforced the growing interest in our products and service for microbiome diagnostics across clinical, pharmaceutical, and consumer health sectors. This development reflects a broader recognition of the microbiome's role in health and...

OSLO, NORWAY/IRVINE, CA, USA – 29 July 2025: Microbiome DX company Genetic Analysis AS (“GA”) and Pangea Laboratory LLC (“Pangea”) announces the launch of the GA-map® MHI GutHealth as a Research Use Only (RUO) test in the USA. As part of the collaboration Pangea will perform analysis in their CLIA-certified, CAP-accredited laboratory in Tustin, California. The GA-map® MHI GutHealth is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. The test has been developed by GA in collaboration with Ferring Pharmaceuticals...

NL0015001BF4 NL0015001OI1 NO0005806802 NO0006390301 NO0010015175 NO0010098247 NO0010257728 NO0010360266 NO0010692130 NO0010713936 NO0010892359 NO0010894231 NO0010963275 NO0011002651 NO0012697715 NO0013119255 NO0013186460 NO0013461350 NZFAPE0001S2 NZGNEE0001S7 SE0000106205 SE0000107203 SE0000112252 SE0000171886 SE0000188518 SE0000195810 SE0000233934 SE0000648669 SE0000671745 SE0000683484 SE0000949331 SE0001057910 SE0001075102 SE0001161654 SE0001552357 SE0001860511 SE0001863291 SE0002110064 SE0002148817 SE0002190926 SE0002485979 SE0003273531 SE0003756758 SE0003815604 SE0003917798 SE0003943620 SE0004210854 SE0004898799 SE0005101003 SE0005162880 SE0005250719 SE0005308558 SE0005392537 SE0005454873 SE0005624756 SE0005768124 SE0005794617 SE0005878741 SE0005881786 SE0005933082 SE0005999836 SE0006091997 SE0006261046 SE0006343745 SE0006421871 SE0006510335 SE0007045414 SE0007074166 SE0007075247 SE0007100359 SE0007158118 SE0007413455 SE0007438577...

Genetic Analysis AS' (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on June 16, 2025 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret). During the period June 5 – June 16, 2025, GA carried out the Subsequent Offering that provided the Company with approximately NOK 4.1 million by issuance of 4,813,194 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises. After this, the...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW. On June 16, 2025, Genetic Analysis AS' (“GA” or the “Company”) announced the preliminary outcome of the Company's subsequent offering with gross...

OSLO, NORWAY - June 18, 2025: Microbiome DX company Genetic Analysis AS ("GA" or the "Company") hereby announces that the direct issue which was announced in a press release on the 05.05.2025 and approved by the Annual General Meeting on 19.05.2025 has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret). The directed issue provided the Company with approximately NOK 12.8 million by issuance of 14 890 576 new shares, before issue costs. The direct issue has now been registered with the Norwegian Register of Business Enterprises. After this, the...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW. The subscription period in Genetic Analysis AS' (“GA” or the “Company”) subsequent offering with gross proceeds of up to approximately NOK 7.1...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm's assets, agreeing, along with a California research institute, to pay $305 million for a cache of customer DNA data...

OSLO, NORWAY – 12 June 2025: Genetic Analysis AS (“GA” or “the Company”) announces that members of the Board and Management have subscribed for shares in the ongoing share offering in GA. Tore Grøttum, Interim CFO in Genetic Analysis AS, has today including oversubscription subscribed for 200.000 new GEAN-shares at a price of 0.86 NOK per share. Tore Grøttum will, following the transaction and provided that the oversubscribed shares are allocated, own 1,834,840 shares following the transaction....

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW. Today, June 12, 2025, is the last day for trading in subscription rights for subscribing for shares in Genetic Analysis AS' (“GA” or the “Company”)...